Azithromycin With Nitazoxanide, Hydroxychloroquine or Ivermectin, With or Without Dutasteride, for Early Stage COVID-19: An Open-Label Prospective Observational Study in Males With Mild-to-Moderate COVID-19 (The Pre-AndroCoV Male Trial)

October 2020 in “ Research Square (Research Square) ”

Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier, J. Philip McCoy

TLDR Men with male pattern baldness had worse COVID-19 symptoms, but early treatment with certain drugs improved outcomes for all.

In this observational study from 2020, 305 males with early-stage COVID-19 were divided into three groups: those without androgenetic alopecia (AGA), those with AGA not using dutasteride, and those with AGA using dutasteride. The study found that males with AGA were more severely affected by COVID-19 in terms of duration of clinical manifestations (14.2 days vs 9.4 days) and viral shedding (17.8 days vs 14.0 days). However, these effects were fully mitigated by the chronic use of dutasteride. The study also found that the combination of early and more sensitive diagnosis of COVID-19 with a variety of drug combinations improved clinical outcomes and prevented progression to more severe states in all patients, regardless of risk factors. The researchers concluded that any additional risk factor can be completely mitigated by combining more sensitive clinical suspicion with early pharmacological approaches.

View this study on researchsquare.com →

Discuss this study in the Community →

Related Community Posts Join

6 / 1000+ results

community Evidenced Based Meta-Analyses and Systemic Reviews of Androgenic Alopecia and Treatments

in Research/Science 13 upvotes 4 years ago

Evidence-based treatments for androgenic alopecia, such as minoxidil, finasteride, low-level laser light therapy, dutasteride, platelet-rich plasma, and topical ketoconazole. It discusses the efficacy, safety, and mechanism of action of these treatments, as well as future developments in understanding this polygenic condition.

community For those on TRT and suffer from a more aggressive type of (AGA) hairloss, what are your hair safe protocols?

in Chat 6 upvotes 1 year ago

People on testosterone replacement therapy (TRT) with aggressive androgenetic alopecia (AGA) discuss using Dutasteride or Finasteride, sometimes combined with topical treatments like RU58841 or CB-03-01 (Breezula), to prevent hair loss. Concerns about side effects and costs of certain treatments are mentioned, with one individual sharing their experience of slowed hair loss using Finasteride alone.

community Been using Dutasteride, Ru58841, Minoxidil, and Ketaconozole for years. Still can't stop shed, recession or loss of density.

in Treatment 1 upvotes 1 week ago

Despite using dutasteride, RU58841, minoxidil, and ketoconazole for years, the user continues to experience severe hair loss and thinning. They seek advice after multiple dermatologists confirmed androgenetic alopecia (AGA) but offered no effective solutions.

community SCUBE3 and GT20029 could be the closet thing to a cure: Hair Follicle Regeneration and Protection Against DHT

in Research/Science 14 upvotes 1 year ago

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

community I’m Feeling so discouraged and depressed - No one wants to prescribe finasteride to me.

in Finasteride/Dutasteride 68 upvotes 6 months ago

A user in France is frustrated because three dermatologists refused to prescribe finasteride for their hair loss, suggesting it's not androgenetic alopecia (AGA) and offering expensive vitamin treatments instead. Other users suggest buying hair loss treatments like minoxidil and finasteride from various online pharmacies and considering a gender-affirming care physician for more understanding treatment options.

community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

in Research/Science 134 upvotes 5 months ago

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Related Research

2 / 2 results

Azithromycin With Nitazoxanide, Hydroxychloroquine or Ivermectin, With or Without Dutasteride, for Early Stage COVID-19: An Open-Label Prospective Observational Study in Males With Mild-to-Moderate COVID-19 (The Pre-AndroCoV Male Trial)

research Azithromycin With Nitazoxanide, Hydroxychloroquine or Ivermectin, With or Without Dutasteride, for Early Stage COVID-19: An Open-Label Prospective Observational Study in Males With Mild-to-Moderate COVID-19 (The Pre-AndroCoV Male Trial)

1 citations, October 2020 in “Research Square (Research Square)”

Men with male pattern baldness had worse COVID-19 symptoms, but early treatment with certain drugs improved outcomes for all.

research Azithromycin With Nitazoxanide, Hydroxychloroquine or Ivermectin, With or Without Dutasteride, for Early Stage COVID-19: An Open-Label Prospective Observational Study in Males With Mild-to-Moderate COVID-19 (The Pre-AndroCoV Male Trial)

4 citations, October 2020 in “Research Square (Research Square)”

Early treatment with certain drug combinations improved COVID-19 outcomes and prevented severe disease in males, including those at higher risk.